Why Seres Therapeutics Stock Is Crashing Today

What happened

Shares of Seres Therapeutics (NASDAQ: MCRB) were crashing 57.3% lower as of 11 a.m. EDT on Thursday. The steep decline came after the company announced top-line results from a phase 2b clinical study evaluating SER-287 in treating ulcerative colitis (UC).

So what

With the biotech stock losing more than half of its value today, it’s no surprise that Seres’ clinical results weren’t good. The company reported that the primary endpoint of improving clinical remission rates wasn’t met.

Image source: Getty Images.

There were three patient cohorts in the clinical study. Sixty-eight patients were given a full induction dose of SER-287. Another 66 patients were given a step-down induction dose. Placebo was administered to the remaining 69 patients. Seres said that there were “no meaningful clinical differences” observed between these three cohorts.

Seres CEO Eric Shaff acknowledged that “these outcomes were not what we, nor the UC community, were hoping for.” Because of the poor results, the company is closing the open-label and maintenance parts of the phase 2b study.

Now what

The main thing to watch with Seres now is its anticipated regulatory filing for approval of SER-109 in treating recurrent Clostridioides difficile infection. The company recently signed a deal with Nestlé Health Science to co-market the drug pending approval.

10 stocks we like better than Seres Therapeutics
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now… and Seres Therapeutics wasn’t one of them! That’s right — they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of June 7, 2021

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Nestle. The Motley Fool has a disclosure policy.

You May Also Like

About the Author: Over 50 Finance